At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 440 enrolled
Drug / intervention
Ramucirumab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 3 Study of Weekly Paclitaxel With or Without Ramucirumab (IMC-1121B) in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma, Refractory to or Progressive After First-Line Therapy With Platinum and Fluoropyrimidine
In Brief
A Phase 3 clinical trial evaluating Ramucirumab, Paclitaxel, and 1 other intervention for Gastroesophageal Junction Adenocarcinoma and Gastric Adenocarcinoma. Completed, enrolled 440 participants across 32 sites in 4 countries.
Detailed Summary
The purpose of this study is to evaluate the efficacy of the study drug known as ramucirumab in participants with gastric and gastroesophageal cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina, Malaysia, Philippines, Thailand
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedSep 2016
Enrollment StartMar 2017
Primary CompletionJun 2020
Study CompletionApr 2021
TodayJul 2026
First PostedSep 13, 2016
Enrollment StartMar 2, 2017
Primary CompletionJun 30, 2020
Study CompletionApr 12, 2021
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 9.8 years ago
Interventions
Ramucirumabdrug
Administered IV
Paclitaxeldrug
Administered IV
Placebodrug
Administered IV